From Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs:

msouza_cropped

msouza_cropped—

Photo of Praxis Precision Medicines CEO Marcio Souza. Photo by Praxis.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
How to Approach Life Sciences Fundraising
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

From Our Editors · Special Report
Xcelerating Life Sciences San Francisco: Special Report
The AI, Big Data, and R&D Boom

Xconomy on Demand

We offer a number of ways to subscribe for free!